Speaker's Highlight

• Don Sin University of British Columbia, St. Paul Hospital (Canada)
  Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
• Parameswaran Nair McMaster University (Canada)
  Carolyn Calfee UCSF (U.S.A.)
• Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
  David A. Schwartz University of Colorado School of Medicine (U.S.A.)
• Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
  Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
• Nicola Hananiah Baylor College of Medicine (U.S.A.)
  Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
• Koichiro Asano Tokai University School of Medicine (Japan)
  Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
• Konstantinos Kostikas University of Ioannina (Greece)
  Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)

• Quality Of Life Measures In Bronchiectasis Clinical Trials

  Bronchiectasis clinical trials increasingly assess outcomes that extend beyond exacerbation frequency, sputum microbiology, and lung function. These clinical markers remain important, yet they do not fully describe how chronic cough, fatigue, breathlessness, pain, sleep disruption, and treatment workload affect daily living.

  Patient-reported outcome measures (PROMs) give researchers a structured way to capture these experiences. When selected and analyzed carefully, health-related quality of life (HRQoL) instruments can show whether an intervention makes a meaningful difference to patients, even when changes in spirometry or imaging are modest.

  Respiratory specialists presenting research through congresses such as APSR 2022 and KATRD contribute to a broader effort to define clinically useful endpoints. The event’s conference message reflects the value of collaboration across respiratory medicine, clinical research, and patient care.

  Why Quality Of Life Matters

  Bronchiectasis is a heterogeneous airway disease. Some patients experience frequent pulmonary exacerbations, while others have persistent sputum production, recurrent infections, exercise limitation, or anxiety about sudden deterioration. A trial endpoint must be sensitive to this variation.

  Quality of life measures can reveal benefits that conventional physiological outcomes miss. An antibiotic, airway-clearance intervention, inhaled therapy, or rehabilitation program may reduce symptom burden or treatment disruption without producing a large change in forced expiratory volume. Capturing those effects improves the clinical relevance of trial findings.

  HRQoL data also support shared decision-making. Patients and clinicians can weigh a therapy’s adverse effects, administration time, and costs against improvements in energy, social participation, sleep, or confidence in managing symptoms.

  Selecting Appropriate Patient-Reported Outcomes

  Disease-specific questionnaires are generally valuable because they focus on problems that matter in bronchiectasis. The Quality of Life-Bronchiectasis (QoL-B) questionnaire, the St George’s Respiratory Questionnaire, and the Leicester Cough Questionnaire are examples of instruments used to evaluate respiratory symptoms, physical functioning, emotional wellbeing, and social impact.

  Generic measures such as the EQ-5D or SF-36 provide a wider health perspective. They can support comparisons across diseases and economic evaluations, but they may be less responsive to bronchiectasis-specific changes. A strong protocol may therefore combine one disease-specific instrument with a generic measure.

  Researchers should define the primary quality of life endpoint before recruitment begins. The selected questionnaire must have evidence of reliability, validity, responsiveness, and a known minimal clinically important difference (MCID) in a relevant population. Translation and cultural adaptation also require formal validation rather than informal wording changes.

  Comparing Measures And Trial Uses

  Different instruments serve different purposes. A short symptom questionnaire may reduce participant burden and work well for frequent monitoring, whereas a broader HRQoL tool may be better for baseline characterization and long-term follow-up.

  Measure or approach	Main focus	Strengths	Important considerations
  Quality of Life-Bronchiectasis	Disease-specific physical, social, and emotional impact	Broad relevance to bronchiectasis	Longer completion time may affect adherence
  Leicester Cough Questionnaire	Cough-related physical, psychological, and social effects	Sensitive to cough burden	May not capture the full treatment experience
  St George’s Respiratory Questionnaire	Respiratory symptoms and activity limitation	Widely recognized in pulmonary research	Some items may be less specific to bronchiectasis
  EQ-5D	Generic health status and utility values	Useful for health economics	May miss subtle respiratory changes
  Daily electronic symptom diary	Symptoms, treatment use, and exacerbation signals	Captures fluctuations in real time	Requires digital access and consistent engagement

  The best choice depends on the intervention and study duration. A trial of airway clearance may prioritize sputum, cough, and daily activity, while a long-term anti-inflammatory treatment may require measures covering exacerbation recovery, emotional wellbeing, and treatment burden.

  Timing And Data Collection

  Quality of life should be measured at clinically meaningful time points. Baseline assessment establishes the patient’s usual status, but timing is important: questionnaires completed during an acute exacerbation may not represent stable disease. Follow-up should capture both early response and sustained benefit.

  Researchers can pair scheduled assessments with electronic symptom diaries. This approach helps distinguish temporary improvement from durable change and may identify worsening health before a formal exacerbation is reported. However, frequent questionnaires can cause fatigue, especially in participants already managing complex medication routines.

  Missing data need careful attention. Participants may skip assessments when unwell, hospitalized, or overwhelmed by treatment, creating results that overrepresent people who remain engaged. Trial teams should record reasons for missing responses, use validated statistical methods, and report completion rates transparently.

  Interpreting Clinically Meaningful Change

  Statistical significance does not automatically equal patient importance. A small average improvement may reach statistical significance in a large sample yet have little practical value. Conversely, a meaningful benefit for a subgroup can be hidden by variation across the whole cohort.

  The MCID helps translate questionnaire scores into clinically understandable results. Investigators may report the proportion of participants who achieve a predefined improvement, alongside mean score changes and confidence intervals. Responder analyses can be especially useful when treatment effects vary according to baseline symptoms, exacerbation history, or chronic infection.

  Quality of life outcomes should be interpreted with safety data and clinical endpoints. An intervention that improves cough but causes substantial adverse effects may offer limited overall value. Composite interpretations should remain transparent, with prespecified analyses that avoid overstating isolated positive findings.

  Recommendations For Trial Design

  A practical quality of life strategy should be built into the protocol rather than added after data collection. Investigators can strengthen respiratory clinical trials by adopting the following practices:

  • Select a validated bronchiectasis-specific PROM and justify its use in the target population.
  • Define the primary HRQoL endpoint, assessment schedule, and MCID before recruitment.
  • Combine patient-reported outcomes with exacerbation, microbiology, lung function, and treatment-burden data.
  • Use accessible paper or digital formats, with translated versions validated for each study population.
  • Report missing data, responder rates, and subgroup findings alongside average score changes.

  Bringing Patient Experience Into Evidence

  Quality of life measures make bronchiectasis trials more patient-centered and clinically informative. They show whether an intervention helps people breathe, sleep, move, work, and participate in everyday life—not simply whether a numerical test has changed.

  Future studies should involve patients when choosing outcomes, designing questionnaires, and deciding which changes feel worthwhile. Researchers, sponsors, and respiratory networks can use these measures to produce evidence that supports better treatment decisions and reflects the lived burden of bronchiectasis. Incorporating robust HRQoL endpoints into the next trial protocol is a practical step toward more meaningful respiratory care.

  Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
• Mona Bafadhel King’s College London (United Kingdom)
  David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
• James Chalmers University of Dundee (United Kingdom)
  David Price University of Aberdeen (United Kingdom)